Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Myriad Genetics Affirms FY2025 Adj EPS Guidance of $(0.02)-$0.02 vs $0.01 Est; Affirms FY2025 Sales Guidance of $818.000M-$828.000M vs $821.658M Est

Author: Benzinga Newsdesk | November 03, 2025 04:10pm
Myriad Genetics (NASDAQ:MYGN) affirms FY2025 Adj EPS guidance from $(0.02)-$0.02 to $(0.02)-$0.02 vs $0.01 analyst estimate. Affirms FY2025 sales outlook from $818.000 million-$828.000 million to $818.000 million-$828.000 million vs $821.658 million estimate.

Posted In: MYGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist